Journal Scans
Effects of KRAS, BRAF, NRAS, and PIK3CA Mutations on the Efficacy of Cetuximab Plus Chemotherapy in Chemotherapy-Refractory Metastatic Colorectal Cancer: A Retrospective Consortium Analysis
Effects of KRAS, BRAF, NRAS, and PIK3CA on Cetuximab Efficacy in mCRC
W De Roock, B Claes, D Bernasconi, J De Schutter, B Biesmans, G Fountzilas, KT Kalogeras, V Kotoula, D Papamichael, P Laurent-Puig, F Penault-Llorca, P Rougier, B Vincenzi, D Santini, G Tonini, F Cappuzzo, M Frattini, F Molinari, P Saletti, S De Dosso, M Martini, A Bardelli, S Siena, A Sartore-Bianchi, J Tabernero, T Macarulla, F Di Fiore, A Oden Gangloff, F Ciardiello, P Pfeiffer, C Qvortrup, T Plato Hansen, E Van Cutsem, H Piessevaux, D Lambrechts, M Delorenzi, S Tejpar
20100701
2010 Aug 1
Lancet Oncol
Effects of KRAS, BRAF, NRAS, and PIK3CA Mutations on the Efficacy of Cetuximab Plus Chemotherapy in Chemotherapy-Refractory Metastatic Colorectal Cancer: A Retrospective Consortium Analysis
Lancet Oncol. 2010 Aug 1;11(8):753-762, W De Roock, B Claes, D Bernasconi, J De Schutter, B Biesmans, G Fountzilas, KT Kalogeras, V Kotoula, D Papamichael, P Laurent-Puig, F Penault-Llorca, P Rougier, B Vincenzi, D Santini, G Tonini, F Cappuzzo, M Frattini, F Molinari, P Saletti, S De Dosso, M Martini, A Bardelli, S Siena, A Sartore-Bianchi, J Tabernero, T Macarulla, F Di Fiore, A Oden Gangloff, F Ciardiello, P Pfeiffer, C Qvortrup, T Plato Hansen, E Van Cutsem, H Piessevaux, D Lambrechts, M Delorenzi, S Tejpar
TAKE-HOME MESSAGE
Abstract
Abstract
Background: Following the discovery that mutant KRAS is associated with resistance to anti-epidermal growth factor receptor (EGFR) antibodies, the tumours of patients with metastatic colorectal cancer are now profiled for seven KRAS mutations before receiving cetuximab or panitumumab. However, most patients with KRAS wild-type tumours still do not respond. We studied the effect of other downstream mutations on the efficacy of cetuximab in, to our knowledge, the largest cohort to date of patients...
